Even amid political pressure from RFK Jr. and President Trump, as well as failed clinical data on VX-993, Vertex continues to strengthen its position in the cystic fibrosis market. Sales of its three ...
"It's not a cure, but it's the closest thing we have," a doctor said. "Imagine waiting 28 years for a miracle, and then it suddenly happens." That's how Gunnar Esiason, a 28-year-old graduate student ...
Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...
To topple access barriers to Vertex Pharmaceuticals’ potentially lifesaving, yet often out-of-reach cystic fibrosis therapy Trikafta, a buyers club has resurfaced with a plan to introduce a discounted ...
May 5 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab missed Wall Street estimates for quarterly results on Monday due to lower-than-expected sales of its cystic fibrosis (CF) drug Trikafta ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback